Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 149   

Articles published

BMY 49.32 +0.20 (0.41%)
price chart
Bristol-Myers Squibb and Ono Pharmaceutical Co., Ltd. Announce Strategic ...
Bristol-Myers Squibb Company (NYSE:BMY) and Ono Pharmaceutical Co., Ltd. ("Ono") have signed a strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens to help ...
Bristol-Myers Squibb Company : Bristol-Myers Squibb and Ono Pharmaceutical ...  The Wall Street Transcript
Bristol-Myers Expected To Meet Second-Quarter Earnings Estimates  Bidness Etc
Related articles »  
Bristol-Myers Squibb Co. v. Teva Pharms. USA, Inc.
Case Name: Bristol-Myers Squibb Co. v. Teva Pharms. USA, Inc., 752 F.3d 967 (Fed. Cir. June 12, 2014) (Circuit Judges Prost, Plager, and Chen presiding; Opinion by Chen, J.) (Appeal from D. Del.
Bristol-Myers Squibb (BMY) Set to Announce Quarterly Earnings on Thursday
Bristol-Myers Squibb logo Bristol-Myers Squibb (NYSE:BMY) is scheduled to be issuing its Q214 quarterly earnings data on Thursday, July 24th.
Bristol-Myers Squibb Co (NYSE:BMY) And Pfizer Inc. (NYSE:PFE) Eyeing To ...
Dallas, Texas 07/21/2014 (ustradevoice) - Last week Bristol-Myers Squibb Co (NYSE:BMY) and its partner Pfizer Inc. (NYSE:PFE) announced the commencement of enrolling patients unders its Phase IV trial, named Emanate, involving drug Eliquis.
Bristol-Myers Squibb Given Average Rating of �Buy� by Analysts (NYSE:BMY)  Ticker Report
Related articles »  
Bristol-Myers Squibb Company - Product Pipeline Review - 2014
This report provides comprehensive information on the current therapeutic developmental pipeline of Bristol-Myers Squibb Company's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), ...
Analyst Downgrades: SunPower Corporation, Bristol-Myers Squibb Co, and ...  Schaeffers Research (blog)
Bristol-Myers recalls six lots of blood thinner injection  Fox Business
Related articles »  
Bristol-Myers Squibb and Pfizer Announce Enrollment of First Patient in Phase ...
PRINCETON, N.J. & NEW YORK, Jul 17, 2014 (BUSINESS WIRE) -- Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced that the first patient has been enrolled into a Phase IV clinical trial called EMANATE (Eliquis ...
Bristol-Myers Squibb Co (NYSE:BMY), Pfizer Inc. (NYSE:PFE) Enroll Patients ...
Bristol-Myers, Pfizer Report First Patient Enrollment In Phase IV EMANATE Trial  RTT News
Related articles »  
Bristol-Myers Squibb Receives Average Rating of �Buy� from Brokerages (NYSE ...
Bristol-Myers Squibb logo Bristol-Myers Squibb (NYSE:BMY) has been given an average recommendation of �Buy� by the seventeen analysts that are presently covering the company, StockRatingsNetwork reports. Eight investment analysts have rated the ...
Bristol-Myers Squibb Company - Options Insight
NEW YORK (AVAFIN) -- BMY options observed interesting put volume today. The number of put contracts heavily outweighed the number of call contracts in today's trading session.
Bristol-Myers Squibb Given New $43.50 Price Target at Jefferies Group (BMY)  Watch List News (press release)
Related articles »  
2 Reasons to Watch Bristol-Myers Squibb Co
Like many drug majors Bristol-Myers Squibb (NYSE: BMY ) will face heavy losses to generic competition in the years ahead. In an effort to maximize efficiency the company has narrowed its focus to areas with unmet need rather than making incremental ...
Strategic Category Management and Related Procurement Services  Supply & Demand Chain Executive
Related articles »  
Biggest Movers: CBS Corporation, Marathon Petroleum Corp, and Bristol-Myers ...
Heading into the final hours of today's session, three of the top market movers are mass media company CBS Corporation (NYSE:CBS), oil refiner Marathon Petroleum Corp (NYSE:MPC), and pharmaceutical concern Bristol-Myers Squibb Co (NYSE:BMY).
Will This Price Target Decrease Hurt Bristol-Myers Squibb (BMY) Stock Today?
Bristol-Myers Squibb Expands Access to Clinical Trial Data Through ...  Wall Street Journal
Related articles »